Press coverage about Flex Pharma (NASDAQ:FLKS) has trended positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Flex Pharma earned a coverage optimism score of 0.27 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 47.9325049559395 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
A number of analysts have commented on the company. Cantor Fitzgerald reiterated a “hold” rating and issued a $6.00 price objective on shares of Flex Pharma in a research report on Wednesday, March 7th. Zacks Investment Research upgraded Flex Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, February 15th. Ladenburg Thalmann Financial Services assumed coverage on Flex Pharma in a research report on Thursday, January 25th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, Roth Capital reiterated a “buy” rating and issued a $12.00 price objective on shares of Flex Pharma in a research report on Wednesday, January 3rd. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $8.55.
Flex Pharma (NASDAQ:FLKS) traded up $0.37 during trading on Thursday, hitting $6.15. The company had a trading volume of 63,957 shares, compared to its average volume of 70,918. The company has a market cap of $103.70, a P/E ratio of -3.04 and a beta of 3.33. Flex Pharma has a 1-year low of $2.68 and a 1-year high of $6.20.
Flex Pharma (NASDAQ:FLKS) last posted its earnings results on Wednesday, March 7th. The biotechnology company reported ($0.46) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.10. The business had revenue of $0.28 million during the quarter, compared to the consensus estimate of $0.36 million. Flex Pharma had a negative return on equity of 85.02% and a negative net margin of 2,698.59%. sell-side analysts anticipate that Flex Pharma will post -1.88 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Flex Pharma (FLKS) Receives News Impact Score of 0.27” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/03/15/flex-pharma-flks-receives-news-impact-score-of-0-27.html.
Flex Pharma Company Profile
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
Receive News & Ratings for Flex Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma and related companies with MarketBeat.com's FREE daily email newsletter.